We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.94%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$977M
AUM Growth
+$166M
Cap. Flow
+$154M
Cap. Flow %
15.75%
Top 10 Hldgs %
25.96%
Holding
96
New
4
Increased
44
Reduced
31
Closed
7

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$31.5M
2
WBA
Walgreens Boots Alliance
WBA
+$16.4M
3
INCY icon
Incyte
INCY
+$15.4M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$13.2M
5
AET
Aetna Inc
AET
+$12.5M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$13.4M
2
BIIB icon
Biogen
BIIB
+$8.24M
3
CELG
Celgene Corp
CELG
+$7.12M
4
ABMD
Abiomed Inc
ABMD
+$5.83M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.72M

Sector Composition

Rank Sector Weight
1 Healthcare 91.68%
2 Financials 1.43%
3 Energy 0.15%
4 Technology 0.13%
5 Communication Services 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
1
Nektar Therapeutics
NKTR
$2.39B
$30.2M 3.09%
41,177
+27,346
+198% +$31.5M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$27M 2.77%
1,632,212
-375,000
-19% -$5.72M
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$121B
$26.3M 2.7%
155,000
+5,000
+3% +$775K
INCY icon
4
Incyte
INCY
$24.2B
$25.7M 2.63%
383,763
+224,800
+141% +$15.4M
ABMD
5
DELISTED
Abiomed Inc
ABMD
$24.7M 2.53%
60,400
-16,090
-21% -$5.83M
BMY icon
6
Bristol-Myers Squibb
BMY
$133B
$24.4M 2.49%
440,000
+90,000
+26% +$4.86M
CVS icon
7
CVS Health
CVS
$133B
$24.1M 2.46%
373,868
+120,000
+47% +$7.91M
MDT icon
8
Medtronic
MDT
$109B
$24M 2.45%
279,874
+68,591
+32% +$5.73M
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$23.8M 2.44%
191,863
-30,000
-14% -$3.51M
UNH icon
10
UnitedHealth
UNH
$376B
$23.6M 2.41%
96,000
+15,000
+19% +$3.6M
ESRX
11
DELISTED
Express Scripts Holding Company
ESRX
$22.8M 2.33%
295,000
+80,000
+37% +$6M
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.6B
$22.6M 2.31%
239,849
+35,000
+17% +$3.07M
CI icon
13
Cigna
CI
$73.7B
$22.2M 2.27%
130,400
+20,000
+18% +$3.46M
JAZZ icon
14
Jazz Pharmaceuticals
JAZZ
$15.9B
$22.1M 2.26%
128,436
-20,000
-13% -$3.27M
HUM icon
15
Humana
HUM
$43.7B
$21.7M 2.22%
73,000
+5,000
+7% +$1.46M
LOXO
16
DELISTED
Loxo Oncology, Inc
LOXO
$21.3M 2.18%
122,961
+47,961
+64% +$7.21M
AGN
17
DELISTED
Allergan plc
AGN
$20.8M 2.13%
125,045
+65,045
+108% +$10.4M
BDX icon
18
Becton Dickinson
BDX
$45.6B
$20.4M 2.08%
87,125
+10,250
+13% +$2.28M
SAGE
19
DELISTED
Sage Therapeutics
SAGE
$20.3M 2.08%
129,679
+34,679
+37% +$5.44M
EXEL icon
20
Exelixis
EXEL
$13.3B
$20.3M 2.07%
941,214
-45,000
-5% -$931K
WBA
21
DELISTED
Walgreens Boots Alliance
WBA
$19.8M 2.03%
330,000
+255,000
+340% +$16.4M
GILD icon
22
Gilead Sciences
GILD
$162B
$18.6M 1.9%
262,027
+25,000
+11% +$1.77M
ELV icon
23
Elevance Health
ELV
$81.5B
$18.1M 1.85%
76,000
+15,000
+25% +$3.47M
LLY icon
24
Eli Lilly
LLY
$1.02T
$17.1M 1.75%
200,000
-22,859
-10% -$1.88M
CELG
25
DELISTED
Celgene Corp
CELG
$16.7M 1.71%
210,698
-85,714
-29% -$7.12M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2018 Portfolio in Review

As of Q2 2018, Rhenman & Partners Asset Management held 96 positions worth $977M, up 20% from $811M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management deployed $154M of net new capital in Q2 2018, opening 4 new positions and adding to 44 existing holdings. Its largest new stake was Aetna Inc: 70,000 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier, followed by Financials and Energy.

On the sell side, the largest reduction was AbbVie, an estimated $13.4M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2018 buy was Aetna Inc: 70,000 shares worth $12.8M.
  • Rhenman & Partners Asset Management added most to Nektar Therapeutics in Q2 2018, an estimated $31.5M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2018 reduction was AbbVie, cutting an estimated $13.4M.
  • Rhenman & Partners Asset Management fully exited Endologix Inc in Q2 2018, selling an estimated $3.83M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $977M portfolio in Q2 2018.
  • Rhenman & Partners Asset Management opened 4 new positions and closed 7 in Q2 2018.
  • Rhenman & Partners Asset Management's portfolio value rose 20% quarter-over-quarter to $977M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2018, filed 20 Jul 2018.